Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®):: Pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium

被引:75
|
作者
de Haën, C [1 ]
Cabrini, M [1 ]
Akhnana, L [1 ]
Ratti, D [1 ]
Calabi, L [1 ]
Gozzini, L [1 ]
机构
[1] Bracco SpA, Milano Res Ctr, I-20134 Milan, Italy
关键词
gadobenate dimeglumine; MultiHance (R); relaxivity; complex formation constants; pharmaceutical formulation; physicochemical properties;
D O I
10.1097/00004728-199911001-00021
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To characterize the proton-magnetic relaxation properties and complexation equilibria of gadobenate dimeglumine and to develop a pharmaceutical formulation for injection. Methods: Proton-magnetic relaxivities were determined at 20 MHz and 39 degrees C. Metal complexation was studied potentiometrically. Degradation pathways were identified through prolonged exposure to elevated temperature. Results: Because of its size and very weak interaction with serum albumin, gadobenate dimeglumine has proton-magnetic relaxivities that are larger than those of gadopentetate dimeglumine in both water and biological fluids. With regard to metal complexation, the two products are indistinguishable. The metal complexation behavior and thermal stability of the product allowed a pharmaceutical formulation for injection containing 0.5 M gadobenate dimeglumine without excipients. The physicochemical properties of the formulated product were determined. Conclusion: Gadobenate dimeglumine has an elevated T-1-relaxivity, especially in blood plasma. The high stability of the complex guarantees a negligible release of gadolinium ion. Gadobenate dimeglumine 0.5 Mi solution for injection has a shelf life of three years.
引用
收藏
页码:S161 / S168
页数:8
相关论文
共 45 条
  • [21] Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs
    Toft, KG
    Hustvedt, SO
    Grant, D
    Friisk, GA
    Skotland, T
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1997, 22 (01) : 65 - 72
  • [22] Gadobenate dimeglumine in MRI of acute myocardial infarction -: Results of a phase III study comparing dynamic and delayed contrast enhanced magnetic resonance imaging with EKG, 201Tl SPECT, and echocardiography
    Cherryman, GR
    Pirovano, G
    Kirchin, MA
    INVESTIGATIVE RADIOLOGY, 2002, 37 (03) : 135 - 145
  • [23] PHARMACEUTICAL PROPERTIES, BIODISTRIBUTION, AND IMAGING CHARACTERISTICS OF MANGANESE-MESOPORPHYRIN - A POTENTIAL HEPATOBILIARY CONTRAST AGENT FOR MAGNETIC-RESONANCE-IMAGING
    SCHMIEDL, UP
    NELSON, JA
    ROBINSON, DH
    MICHALSON, A
    STARR, F
    FRENZEL, T
    EBERT, W
    SCHUMANNGIAMPIERI, G
    INVESTIGATIVE RADIOLOGY, 1993, 28 (10) : 925 - 932
  • [24] PRECLINICAL SAFETY ASSESSMENT AND PHARMACOKINETICS OF GADODIAMIDE INJECTION, A NEW MAGNETIC-RESONANCE-IMAGING CONTRAST AGENT
    HARPUR, ES
    WORAH, D
    HALS, PA
    HOLTZ, E
    FURUHAMA, K
    NOMURA, H
    INVESTIGATIVE RADIOLOGY, 1993, 28 : S28 - S43
  • [25] Retrospective Assessment of Prevalence of Nephrogenic Systemic Fibrosis (NSF) After Implementation of a New Guideline for the Use of Gadobenate Dimeglumine as a Sole Contrast Agent for Magnetic Resonance Examination in Renally Impaired Patients
    Abujudeh, Hani H.
    Rolls, Hillary
    Kaewlai, Rathachai
    Agarwal, Sheela
    Gebreananya, Zelalem A.
    Saini, Sanjay
    Schaefer, Pamela W.
    Kay, Jonathan
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2009, 30 (06) : 1335 - 1340
  • [26] Intraindividual comparison of 1.0 m gadobutrol and 0.5 m gadopentetate dimeglumine for time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the upper torso
    Fink, C
    Puderbach, M
    Ley, S
    Risse, F
    Kuder, TA
    Bock, M
    Thaler, J
    Plathow, C
    Kauczor, HU
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2005, 22 (02) : 286 - 290
  • [27] Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: In vitro metabolism and protein binding studies of the active component MnDPDP in human blood
    Toft, KG
    Kindberg, GM
    Skotland, T
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1997, 15 (07) : 983 - 988
  • [28] Toxicological assessment of gadoversetamide injection (OptiMARK®), a new contrast-enhancement agent for use in magnetic resonance imaging
    Wible, JH
    Troup, CM
    Hynes, MR
    Galen, KP
    MacDonald, JR
    Barco, SJ
    Wojdyla, JK
    Periasamy, MP
    Adams, MD
    INVESTIGATIVE RADIOLOGY, 2001, 36 (07) : 401 - 412
  • [29] Injection rate of contrast medium affects diagnostic ability of dynamic contrast-enhanced magnetic resonance imaging for endometrial carcinoma: a prospective cohort study
    Xu, Donghui
    Jin, Aiping
    Ge, Yongqian
    Zhang, Yanmei
    GLAND SURGERY, 2021, 10 (08) : 2462 - 2470
  • [30] MAGNETIC-RESONANCE-IMAGING OF THE NEUROONCOLOGY PATIENT - RESULTS USING A NEW LOW OSMOLAL CONTRAST-MEDIUM
    ROSA, L
    SCHELLINGER, D
    FRANCISCO, J
    CARVLIN, M
    ANNALS OF NEUROLOGY, 1991, 30 (02) : 272 - 272